It is well recognized that different patients respond in different ways to the same medication.
These differences are often greater among members of a population than they are within the …

Background The management of warfarin therapy is complicated by a wide variation among
patients in drug response. Variants in the gene encoding vitamin K epoxide reductase …

Genomics and Drug Response | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Cisplatin, carboplatin, and oxaliplatin anticancer drugs are commonly used to treat lung,
colorectal, ovarian, breast, head and neck, and genitourinary cancers. However, the efficacy of …

P-glycoprotein (PGP), the product of the multidrug resistance gene (MDR1), acts as an
energy-dependent efflux pump that exports its substrates out of the cell. PGP expression is an …

Consistent with its highest abundance in humans, cytochrome P450 (CYP) 3A is responsible
for the metabolism of about 60% of currently known drugs. However, this unusual low …

The Food and Drug Administration and Pfizer changed the package insert for irinotecan to
include a patient's UGT1A1*28 genotype as a risk factor for severe neutropenia on the basis …

The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also
critical for tumorigenesis, including cellular proliferation, growth, survival and mobility. …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide …

Purpose The 5-year survival rate of patients with Dukes' B colon cancer is approximately 75%.
Identification of the patients at high risk of recurrence in this group would allow better …